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ABSTRACT 
Objective: Development of RP-HPLC method for determination of Hydrochlorothiazide (HCTZ), Olmesartan medoxomil (OLM) and their related 
substances in combined tablet dosage form and validation of the developed method. 
Methods: Gradient mobile phase system was used for estimation of drug contents and their related substances. Mobile phase A contained the 
mixture of Acetonitrile and 15 mM Phosphate buffer (pH adjusted to 3.4 with orthophosphoric acid) in the ratio of 20:80. Mobile phase B contained 
the same mixture in the ratio of 80:20. Chromatographic separation was carried out at the mobile phase flow rate of 0.8 mL/min using C18
Results: The linearity of developed method was tested in the range of 62.5-187.5 μg/mL for Hydrochlorothiazide, 100-300 μg/mL for Olmesartan 
medoxomil, 1-1.8 μg/mL for Hydrochlorothiazide. The % recovery was found to be 99.88-100.67 % (HCTZ), 99.14-99.91 % (OLM), 99.11-100.71% 
(HCTZ-IMP) and 98.13-100.83% (OLM-IMP). The assay of marketed formulation was found to be 99.78% (HCTZ) and 99.26% (OLM). 
 
Phenomenax inplace of Enable (250 × 4.6 mm) 5 μm column and detection was made at 254 nm. 
Conclusion: A simple, precise and accurate RP-HPLC method was developed for determination of Hydrochlorothiazide, Olmesartan medoxomil and 
their related substances. 
Keywords: Hydrochlorothiazide (HCTZ), Olmesartan medoxomil (OLM), Hydrochlorothiazide Related Impurity (HCTZ-IMP), Olmesartan 
medoxomil Related Impurity (OLM-IMP), Reversed phase high performance liquid chromatography (RP-HPLC). 
 
INTRODUCTION 
Hydrochlorothiazide (HCTZ) is a diuretic antihypertensive drug. 
Chemically it is 6-chloro-3, 4-dihydro-2H-1,2,4-benzothiadiazine-7-
sulphonamide 1,1-dioxide clinically used in treatment of 
hypertension and management of edema. It inhibits the 
reabsorption of sodium in the distal convoluted tubule thereby 
decreasing the blood pressure. 
Olmesartan medoxomil (OLM) is an antihypertensive drug. 
Chemically it is (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(1-
hydroxy-1-methylethyl)-2-propyl-1-[[2′-(1H-tetrazol-5-yl)biphenyl-
4-yl]methyl]-1H-imidazole-5-carboxylate clinically used in the 
treatment of hypertension. Olmesartan is an angiotensin receptor 
blocker that selectively inhibits the binding of Angiotensin II to AT1. 
This results in decreased vascular resistance and blood pressure. 
The literature review reveals various analytical methods for 
determination of Hydrochlorothiazide like UV [1,2], RP-HPLC [3,4], 
and HPTLC [5] and Olmesartan medoxomil UV [6,7], RP-HPLC [8,9] 
and HPTLC [10] individually as well as in combined dosage form 
with other drugs [11,12] but there was no method available for 
determination of these two drugs along with their related 
substances in combined tablet dosage form. There are various 
sources through which impurities (related substances & other 
impurities) may be generated in the drug product affecting its 
efficacy. It becomes necessary to have a method which can analyze 
such impurities in drug product.  
Hydrochlorothiazide and Olmesartan medoxomil both have some 
related substance reported in pharmacopoeias [13,14]. They may be 
present in combined drug product in some amount or may get 
generated in the amount beyond the acceptance limit under worse 
conditions. So, the objective of present work was determination of 
Hydrochlorothiazide, Olmesartan medoxomil and their related 
substances in combined tablet dosage form by validated RP-HPLC 







































Fig. 3: Chlorothiazide (HCTZ-IMP) 
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Fig. 4: Olmesartan acid impurity (OLM-IMP) 
 
MATERIALS AND METHODS 
Instrumentation 
HPLC: Shimadzu LC-20AT system equipped with LC solution 
software, PDA detector, injection volume: 20μL, column: C18
Materials 
 
Phenomenax inplace of Enable (250 × 4.6 mm) 5 μm , Milli Q water 
purification system. 
Standard gift samples of Hydrochlorothiazide, Olmesartan medoxomil 
and their related impurities were provided by Zydus Cadila Healthcare 
Ltd. Combined tablet dosage form OLMEZEST H-20 was purchased from 
local market. Acetonitrile (HPLC Grade) was procured from Loba Chemie 
Pvt Ltd, Mumbai. Potassium dihydrogen phosphate (HPLC Grade) was 
used for preparation of buffer solution. 
Chromatographic conditions 
The chromatographic column used was C18
Mobile phase A- Acetonitrile: 15 mM Phosphate buffer (pH 3.4) in 
the ratio of 20:80 
 Phenomenax inplace of 
Enable (250 × 4.6 mm) 5 μm. The gradient method was employed 
with mobile phase A & B using 0.8 mL/min flow rate and 254 nm 
detection wavelength during entire gradient program. Injection 
volume was 20 μL. 
Mobile phase B- Acetonitrile: 15 mM Phosphate buffer (pH 3.4) in 
the ratio of 80:20 
 
Table 1: Gradient Program 
Time (min) A (% v/v) B (% v/v) 
0-26 87→13 13→87 
26-27 13→87 87→13 
27-30 87 13 
 
Preparation of Solutions  
Preparation of standard stock solutions 
Stock solutions of 1250 μg/mL of HCTZ and 2000 μg/mL of OLM 
were prepared by dissolving 125 mg of HCTZ and 200 mg of OLM in 
100 mL of acetonitrile in separate 100 mL volumetric flasks 
respectively. 
HCTZ-IMP (4 mg) was accurately weighed and transferred to a 10 
mL volumetric flask and then dissolved and diluted to 10 mL with 
acetonitrile. From above solution 1 mL was transferred to a 10 mL 
volumetric flask and diluted to 10 mL with acetonitrile to obtain 
stock solution of 40 µg/mL. 
OLM-IMP (5 mg) was accurately weighed and transferred to a 10 mL 
volumetric flask and then dissolved and diluted to 10 mL with 
acetonitrile. From above solution 2 mL was transferred to a 10 mL 
volumetric flask and diluted to 10 mL with acetonitrile to obtain 
stock solution of 100 µg/mL. 
Validation of developed method 
The developed method was validated according to International 
Conference on Harmonization (ICH) Q2(R1) guideline. 
System suitability 
They are used to verify that resolution and reproducibility of 
chromatographic system are adequate for the analysis to be done. 
The parameters include Resolution (R), Tailing factor (T), 
Theoretical plates and Precision of replicate injection.  
Linearity 
Linearity of response was assessed by calibration curve in terms of 
slope, intercept and regression coefficient values. Five standard 
mixture solutions of HCTZ (62.5-187.5 µg/mL), OLM (100-300 
µg/mL), HCTZ-IMP (1-1.8 µg/mL) and OLM-IMP (1-3 µg/mL) were 
analyzed for linear regression analysis.  
Precision 
Intraday and interday precision were performed over 3 levels of 
concentration at 3 different times in a day and on 3 different 
consecutive days respectively. Concentration levels of standard 
mixture of HCTZ, OLM, HCTZ-IMP and OLM-IMP used were 50%, 
100% and 150% of the test concentration. 
Specificity 
Specificity for drug substances was assessed by taking the overlay of 
chromatograms of standard and sample. Specificity for impurities 
was assessed by taking the overlay of chromatogram of sample (i. e. 
drug product) and that of the mixture of impurity standards & drug 
substances. 
Accuracy (n=3) 
Accuracy was determined in terms of percentage recovery. Accuracy 
was determined by spiking 3 different known concentrations of 
standard to sample solution to obtain three levels of concentrations 
(80%, 100% and 120%).  
Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
LOD and LOQ were determined using following equations. 
LOD = 3.3 σ/S 
LOQ = 10 σ/S 
Where, σ = Standard deviation of response 
S = Slope of calibration curve 
Robustness 
The developed HPLC method was tested for robustness using 
factorial design (23-1
 
) with four experiments. Three factors selected 
were Flow rate, Mobile phase ratio in line A and pH of buffer 
solution. The selection of factors was based on observation during 
method development. Each factor was studied at two levels. The 
levels of factors studied were selected according to error ranges 
which would be typically encountered in an analytical laboratory. 
Table 2: Selected factors and levels 
S. 
No. 




1. Mobile phase ratio in line 
A 
15:85 25:75 
2. pH of buffer solution 3.2 3.6 
3. Flow rate 0.7 0.9 
 




Mobile phase in line 
A 




1. 15:85 3.2 0.7 
2. 25:75 3.2 0.9 
3. 15:85 3.6 0.9 
4. 25:75 3.6 0.7 
 
Analysis of marketed formulation 
Twenty tablets were powdered and the powder quantity equivalent 
to 200 mg of OLM and 125 mg of HCTZ was accurately weighed and 
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transferred to a 100 mL volumetric flask. 50 mL of acetonitrile was 
added to dissolve the drug content and solution was filtered. The 
filtrate solution was diluted to 100 mL using acetonitrile. From 
above solution, 1 mL was transferred to a 10 mL volumetric flask 
and diluted to 10 mL with mixture of acetonitrile and water (50:50) 
to obtain final solution of 200 µg/mL (OLM) and 125 µg/mL (HCTZ). 
The amount of both the drugs was calculated from regression 
equation of calibration curve and percentage assay was calculated. 
Forced degradation of marketed formulation 
Sample solution of marketed formulation was prepared containing 
2500 µg/mL OLM and 1562.5 µg/mL HCTZ. This solution was used 
as stock solution for degradation. 
Acidic degradation 
10 mL of above stock solution was transferred to a 100 mL 
volumetric flask and 10 mL of 0.1N HCl was added to it. Solution was 
kept for 60 min at room temperature and then it was neutralized. 
The final volume was made up to 100 mL using mixture of 
acetonitrile and water (50:50). 
Alkaline degradation 
10 mL of stock solution was transferred to a 100 mL volumetric 
flask and 10 mL of 0.1N NaOH was added to it. Solution was kept for 
30 min at room temperature and then it was neutralized. The final 
volume was made up to 100 mL using mixture of acetonitrile and 
water (50:50). 
Oxidative degradation 
10 mL of stock solution was transferred to a 100 mL volumetric 
flask and 10 mL of 5% H2O2
The degraded samples were subjected to HPLC analysis using 
developed method and the percentage impurity of interest was 
calculated using following equation. 
 was added to it. Solution was kept for 
60 min at room temperature. The final volume was made up to 100 
mL using mixture of acetonitrile and water (50:50). 
% Impurity = (Area of that impurity peak / Total Area of all peaks) * 100 
RESULTS AND DISCUSSION 
Optimization of chromatographic condition 
The retention time was found to be 6.194 min (HCTZ), 8.389 min 
(HCTZ-IMP), 15.226 min (OLM) and 19.309 min (OLM-IMP). 
 
 
Fig. 5: Chromatogram of Mixture of HCTZ, HCTZ-IMP, OLM & 
OLM-IMP (125, 1.4, 200 & 2 μg/mL in ACN:Water-50:50 
respectively) 
 
System Suitability Test 
Results of theoretical plate, tailing factor, resolution and precision of 
injection repeatability have been shown below (Table 4). 
 
Table 4: Data of System Suitability Test (n=6) 
Parameter HCTZ OLM HCTZ-IMP OLM-IMP 
Retention Time (min) ±SD 6.194±0.021 15.16±0.115 8.380±0.014 19.279±0.053 
Tailing Factor ±SD 1.343±0.030 1.481±0.065 0.929±0.043 1.346±0.014 
Theoretical Plate ±SD 2363.281 ± 214.089 29127.175 ± 1128.663 1797.433 ± 91.445 51571.147 ± 1031.876 
Resolution  - 11.908 3.373 11.717 
%RSD (Injection repeatability) 0.95 1.72 0.64 0.54 
 
Linearity 
The data of linearity of HCTZ, OLM, HCTZ-IMP and OLM-IMP has been 
shown below (Table 5). The results are within the acceptance criteria. 
Precision 
The % RSD for Intraday and Interday precision were found to be less 
than 2 for HCTZ, OLM, HCTZ-IMP and OLM-IMP which indicates that 
the developed method is precise.  
The results of precision study have been shown below (Intraday: 
Table 7 & Table 8) (Interday: Table 9 & Table 10). 
 
 
Fig. 6: Overlay Chromatogram for Linearity of HCTZ, OLM, 
HCTZ-IMP, OLM-IMP. 
Specificity 
Overlay of chromatograms for specificity has been shown below (fig. 
7 and fig. 8). 
 
 
Fig. 7: Overlay Chromatogram of Standard & Sample for 
Specificity of HCTZ & OLM. 
 
Accuracy 
Accuracy study was performed at three levels for HCTZ, OLM, HCTZ-
IMP and OLM-IMP (Table 11 and 12). The values of % recovery were 
found in the acceptance limit of 98-102 % with low % RSD, which 
justifies that, the method is accurate and free from the interference 




Table 5: Linear regression data of HCTZ, OLM, HCTZ-IMP, OLM-IMP 
Parameter HCTZ OLM HCTZ-IMP OLM-IMP 
Regression equation y = 30,571.4944x + 
291,450.4 
y = 47,953.4380x - 
57,777.4 
y = 188,952.50x - 
73,059.9 
y = 35,586.80x + 
104,769.8 
Regression coefficient mean ±SD 0.997±0.00037 0.998±0.00032 0.999±0.00030 0.997±0.00089 
Mean of intercept ±SD 291,450.4 ± 12269.537 57,777.4 ± 3303.837 73,059.9 ± 2436.1 104,769.8 ± 1141.972 




54038.647 to 61516.153 70303.113 to 75816.687 103477.499 to 
106062.101 
Slope ±SD 30,571.4944 ± 196.99 47,953.4380 ± 489.83 188,952.50 ± 1563.52 35,586.80 ± 692.49 




46993.372 to 48913.504 185888.001 to 
192016.999 
34803.151 to 36370.449 
 
 
Fig. 8: Overlay Chromatogram of Standard spiked with 
impurities and Sample for Specificity of HCTZ-IMP & OLM-IMP 
Table 6: LOD and LOQ data 
 HCTZ OLM HCTZ-IMP OLM-IMP 
LOD (μg/mL) 1.32 5.08 0.04 0.10 
LOQ (μg/mL) 4.01 15.39 0.13 0.32 
 
Robustness 
The effect of 3 factors on the response was analyzed using design 
expert software and p-value was obtained for each factor. The p-
value for factors Mobile phase ratio in line A and pH of buffer 
solution were found to be greater than 0.05 which indicates that 
they are non significant factors within the study range of factors for 
robustness. The p-value of factor Flow rate was found to be less than 
0.05 for HCTZ and OLM which indicates that flow rate is a significant 
factor affecting the response of HCTZ and OLM. 
 
Table 7: Intraday Precision Data of HCTZ & OLM (n=3) 
HCTZ OLM 
Conc. (μg/mL) Mean Area ± SD %RSD Conc. (μg/mL) Mean Area ± SD %RSD 
62.5  2098427 ± 4553.48 0.22 100 4585538 ± 1659.25 0.04 
125  4144189 ± 9575.98 0.23 200 9648941 ± 83119.86 0.86 
187.5 5967782 ± 24816.77 0.42 300 14137073 ± 65355.89 0.46 
 
Table 8: Intraday Precision Data of HCTZ-IMP & OLM-IMP (n=3) 
HCTZ-IMP OLM-IMP 
Conc. (μg/mL) Mean Area ± SD %RSD Conc. (μg/mL) Mean Area ± SD %RSD 
1  114895 ± 1537.68 1.34 1 138950 ± 425.61 0.31 
1.4  192754 ± 614.51 0.32 2 175622 ± 88.15 0.05 
1.8 265152 ± 170.28 0.06 3 211829 ± 1407.87 0.66 
 
Table 9: Interday Precision Data of HCTZ & OLM (n=3) 
HCTZ OLM 
Conc. (μg/mL) Mean Area ± SD %RSD Conc. (μg/mL) Mean Area ± SD %RSD 
62.5  1930766 ± 10293.61 0.53 100 4543694 ± 56438.02 1.24 
125  4090065 ± 39388.14 0.96 200 10149030 ± 119970.5 1.18 
187.5 6222916 ± 654.82 0.01 300 15401259 ± 39407.02 0.26 
 
Table 10: Interday Precision Data of HCTZ-IMP & OLM-IMP (n=3) 
HCTZ-IMP OLM-IMP 
Conc. (μg/mL) Mean Area ± SD %RSD Conc. (μg/mL) Mean Area ± SD %RSD 
1  113193 ± 2015.28 1.78 1 121755 ± 1495.97 1.22 
1.4  215568 ± 1808.22 0.84 2 180156 ± 1315.37 0.73 
1.8 281837 ± 1262.29 0.46 3 220241 ± 2198.62 0.99 
 
Analysis of marketed formulation 
Marketed formulation OLMEZEST H-20 containing 20 mg of OLM 
and 12.5 mg of HCTZ was used for assay purpose.  Tablet powder 
was dissolved, filtered and diluted to make the final concentration of 
200 μg/mL (OLM) and 125 μg/mL (HCTZ). Along with the peaks of 
HCTZ and OLM, a small peak at 8.386 min was obtained which is a 
peak of HCTZ Related substance (i. e. HCTZ-IMP) present in 
marketed formulation. 
Forced degradation of marketed formulation:  
The tablet sample was subjected to acidic, basic and oxidative 
degradation to generate the impurities in sample.  The impurities of 
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interest were quantified using regression equation obtained from 
calibration curves of impurity standards. In all three conditions for 
degradation of marketed formulation, HCTZ-IMP was generated in 
more amounts and OLM-IMP was generated in very less amount 
because the chromatogram of marketed formulation without 
degradation shows that the HCTZ Related Impurity was already 
present within the acceptance limit and after degradation its amount 
got increased. 
 
Table 11: Accuracy Data of HCTZ & OLM 
 Sample (μg/mL) Std added (μg/mL) Total 
(μg/mL) 
Mean Area ± SD % 
RSD 




75 60 135 4446142±54748.6 1.23 135.90 100.67 
75 75 150 4871521±57179.3 1.17 149.82 99.88 
75 90 165 5354073±43326.3 0.81 165.60 100.36 
 
OLM 
120 96 216 10211399±139896.2 1.37 214.15 99.14 
120 120 240 11370489±89519.63 0.79 238.32 99.30 
120 144 264 12591083±10306.66 0.08 263.77 99.91 
 
 
Table 12: Accuracy Data of HCTZ-IMP & OLM-IMP 
 (HCTZ + OLM) (μg/mL) Impurity Std spiked 
(μg/mL) 
Mean Area±SD % RSD Spiked Std found 
(μg/mL) 
% Recovery 
HCTZ IMP 125 + 200 1.12 137886±822.50 0.59 1.11 99.11 
125 + 200 1.4 192577±622.73 0.32 1.41 100.71 
125 + 200 1.68 243042±1200.65 0.49 1.67 99.40 
OLM IMP 125 +200 1.6 160769±1087.36 0.67 1.57 98.13 
125 + 200 2 175133±434.17 0.25 1.97 98.50 
125 + 200 2.4 191004±763.04 0.39 2.42 100.83 
 
Table 13: p-values of factors for robustness 
 p-value of factors 
Mobile Phase Ratio in line A pH of buffer solution Flow rate 
HCTZ 0.9166 0.8075 0.0223 
OLM 0.9700 0.8175 0.0173 
HCTZ-IMP 0.7276 0.2360 0.4151 
OLM-IMP 0.6794 0.7586 0.0841 
p-value < 0.05: Factor has significant effect on response, p-value > 0.05: Factor has no significant effect on response 
 
 
Fig. 9: Chromatogram of marketed formulation 
 
 
Fig. 10: Acidic degradation of tablet sample 
 
Fig. 11: Alkaline degradation of tablet sample 
 
 
Fig. 12: Oxidative degradation of tablet sample 
 
Table 14: Data of Marketed formulation Analysis 
 Mean Area±SD % RSD % Assay 
HCTZ (125 μg/mL) 4104467±5848.43 0.14 99.78 % 
OLM (200 μg/mL) 9461639±88939.41 0.94 99.26 % 
HCTZ-IMP 139486±727.99 0.52 1.01 % 
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Table 15: Acidic degradation data 
Impurity Retention Time (min) Peak Area Conc. found (μg/mL) % Impurity 
HCTZ-IMP 8.278 850913 4.89 5.79 % 
OLM-IMP 18.795 110533 0.16 0.75 % 
 
Table 16: Alkaline degradation data 
Impurity Retention Time (min) Peak Area Conc. found (μg/mL) % Impurity 
HCTZ-IMP 8.148 664499 3.90 4.10 % 
OLM-IMP 19.466 119840 0.42 0.74 % 
 










8.537 396041 2.48 4.94 % 
OLM-
IMP 
19.550 117986 0.37 1.47 % 
 
CONCLUSION 
The developed method was validated as per ICH Q2(R1) guideline 
and was found to be within the prescribed limit. It concludes that the 
developed method is simple, accurate, sensitive and precise and 
suitable for routine quality control analysis of Hydrochlorothiazide, 
Olmesartan medoxomil and their related substances in combined 
tablet dosage form. 
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